{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Pan M"],"funding":["Natural Science Foundation Project of Chongqing","Science and Technology Research Program of Chongqing Education Commission"],"pagination":["7905"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10178757"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(9)"],"pubmed_abstract":["Hepatocellular carcinoma (HCC), the major type of liver cancer, causes a high annual mortality worldwide. RAD51 is the critical recombinase responsible for homologous recombination (HR) repair in DNA damage. In this study, we identified that RAD51 was upregulated in HCC and that RAD51 silencing or inhibition reduced the proliferation, migration, and invasion of HCC cells and enhanced cell apoptosis and DNA damage. HCC cells with the combinatorial treatments of RAD51 siRNA or inhibitor and sorafenib demonstrated a synergistic effect in inhibiting HCC cell proliferation, migration, and invasion, as well as inducing cell apoptosis and DNA damage. Single RAD51 silencing or sorafenib reduced RAD51 protein expression and weakened HR efficiency, and their combination almost eliminated RAD51 prote"],"journal":["International journal of molecular sciences"],"pubmed_title":["RAD51 Inhibition Shows Antitumor Activity in Hepatocellular Carcinoma."],"pmcid":["PMC10178757"],"funding_grant_id":["no. KJQN202100424","no. cstc2018jcyjAX0825"],"pubmed_authors":["Qiu J","Xia J","Liu L","Luo M","Sha Y","Chen Y","Huang A","Pan M"],"additional_accession":[]},"is_claimable":false,"name":"RAD51 Inhibition Shows Antitumor Activity in Hepatocellular Carcinoma.","description":"Hepatocellular carcinoma (HCC), the major type of liver cancer, causes a high annual mortality worldwide. RAD51 is the critical recombinase responsible for homologous recombination (HR) repair in DNA damage. In this study, we identified that RAD51 was upregulated in HCC and that RAD51 silencing or inhibition reduced the proliferation, migration, and invasion of HCC cells and enhanced cell apoptosis and DNA damage. HCC cells with the combinatorial treatments of RAD51 siRNA or inhibitor and sorafenib demonstrated a synergistic effect in inhibiting HCC cell proliferation, migration, and invasion, as well as inducing cell apoptosis and DNA damage. Single RAD51 silencing or sorafenib reduced RAD51 protein expression and weakened HR efficiency, and their combination almost eliminated RAD51 prote","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Apr","modification":"2025-04-21T22:43:29.89Z","creation":"2025-04-05T18:52:32.129Z"},"accession":"S-EPMC10178757","cross_references":{"pubmed":["37175611"],"doi":["10.3390/ijms24097905"]}}